Article
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
Blood - 3 Jan 2013
Paschka Peter, Du Juan, Schlenk Richard F, Gaidzik Verena I, Bullinger Lars, Corbacioglu Andrea, Späth Daniela, Kayser Sabine, Schlegelberger Brigitte, Krauter Jürgen, Ganser Arnold, Köhne Claus-Henning, Held Gerhard, von Lilienfeld-Toal Marie, Kirchen Heinz, Rummel Mathias, Götze Katharina, Horst Heinz-August, Ringhoffer Mark, Lübbert Michael, Wattad Mohammed, Salih Helmut R, Kündgen Andrea, Döhner Hartmut, Döhner Konstanze
Abstract excerpt
In this study, we evaluated the impact of secondary genetic lesions in acute myeloid leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11. We studied 176 patients, all enrolled on prospective treatment trials, for secondary chromosomal aberrations and mutations in N-/KRAS, KIT, FLT3, and JAK2 (V617F) genes. Most frequent chromosomal aberrations were trisomy 22 (18%) and trisomy 8 (16%)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
